Overview of Melatonin-SZ

Quick Facts

Property	Description
Active Ingredient	Melatonin (N-acetyl-5-methoxytryptamine)
Form	Oral Solid Formulation (e.g., tablet, capsule)
Pharmacological Class	Chronobiotic / Sleep-regulating agent
Common Use	Regulation of the sleep-wake cycle
Origin	Synthetic Analog of an Endogenous Hormone

What is Melatonin-SZ and What Type of Medicine Is It?

Melatonin-SZ is a proprietary pharmaceutical preparation classified as a Chronobiotic and a Sleep-regulating agent. It is an oral medicine defined by its single active ingredient, Melatonin (N-acetyl-5-methoxytryptamine). This classification positions it as an agent used to influence the timing and organization of the body’s intrinsic daily rhythms. The preparation is typically supplied as an oral solid formulation, necessitating the oral route of administration. Melatonin is clinically recognized for its role in signaling sleep onset, making it a focus of pharmacological studies supporting its use in certain sleep-related contexts.

Composition and Origin: Is Melatonin-SZ Natural or Synthetic?

While Melatonin is an endogenous indoleamine hormone naturally synthesized by the human body from tryptophan, the component in Melatonin-SZ is a synthetic analog produced through chemical manufacturing. This synthetic compound is chemically identical to the natural hormone. The preparation's high-level composition includes this active substance and various essential pharmaceutical excipients (such as binders and fillers) necessary to form the stable dosage unit. Melatonin-SZ is often distinguished by its specific formulation technology, which focuses on providing a consistent release profile suitable for supporting adult sleep architecture.

General Purpose: How Melatonin-SZ Supports Sleep

The general purpose of Melatonin-SZ is to assist in the synchronization of the sleep-wake cycle by reinforcing the signal for sleep readiness. The preparation influences the circadian rhythm by interacting with specific receptors in the brain. For instance, it may be used in scenarios where the internal clock is misaligned, such as adjusting after significant time zone travel. This action aids in promoting the state of sleep readiness and modulating the timing of sleep when the body’s internal cycle is disrupted or misaligned.

Regulatory References

NIH: Melatonin and the Sleep-Wake Cycle

What side effects are possible with Melatonin-SZ?

Possible Side Effects and Safety Information

The safety profile for Melatonin-SZ, consistent with official regulatory documents, details adverse reactions organized by frequency and the physiological system affected. The regulatory definition of Common side effects (may affect up to 1 in 10 people) includes reactions such as headache, somnolence (drowsiness), and nausea.

Uncommon side effects (may affect up to 1 in 100 people) span several system-organ classes, including Gastrointestinal Disorders (e.g., abdominal pain, dry mouth, vomiting), Nervous System Disorders (e.g., dizziness, psychomotor hyperactivity), and Psychiatric Disorders (e.g., irritability, nervousness, nightmares).

Reactions categorized as Rare (may affect up to 1 in 1,000 people) involve effects such as thrombocytopenia or leukopenia (blood disorders), disorientation, and certain skin reactions like rash. Serious adverse events, including hypersensitivity reactions (allergic reactions) and angioedema (swelling beneath the skin), are also documented, with a frequency classified as Not Known (cannot be estimated from available data).

Safety characteristics documented in official labeling address population constraints. Melatonin-SZ should not be used in individuals with severe hepatic impairment, a specific safety-related restriction. Furthermore, time-related safety patterns indicate that effects such as somnolence and dizziness are more likely to be experienced near the time of drug administration.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for the active substance in Melatonin-SZ is based on documented clinical reports and regulatory surveillance, with management focusing on supportive care due to the lack of a specific antidote.

Documented Manifestations

Overdose presentations primarily involve the central nervous system, gastrointestinal, and cardiovascular systems. Commonly reported manifestations include excessive sleepiness, dizziness, headache, confusion, and vomiting. Physiological signs documented in severe cases include hypotension (low blood pressure), tachycardia (fast heart rate), and hypothermia (low body temperature).

When to Seek Urgent Medical Attention

Regulators mandate seeking immediate medical attention when severe or life-threatening symptoms are observed. Urgent medical services (e.g., calling 9-1-1) are required if the person is unconscious, experiencing seizures, or has difficulty breathing. In all cases of suspected overdose, contact with a Poison Control Center (1-800-222-1222 in the U.S.) is advised for medical guidance.

Serious Outcomes and Management

Documented serious outcomes, primarily associated with unintentional pediatric ingestions, include the need for mechanical ventilation and rare instances of death. Management is symptomatic and supportive, often requiring hospital monitoring and control of vital signs until the substance is cleared. The pediatric population, particularly children under 5 years, is noted to be most susceptible to serious effects.

Therapeutic Uses of Melatonin-SZ

The active substance melatonin is commonly used in situations involving certain distressing symptoms related to sleep. This medicine is considered relevant for managing symptom clusters that may become intense or disruptive to rest, primarily focusing on managing symptoms of primary insomnia characterized by poor quality of sleep.

This medication is applied in addressing symptomatic discomfort in conditions involving delayed sleep onset, an irregular sleep-wake cycle (such as jet lag), and pre-sleep restlessness. It is relevant across domains where additional symptomatic support is needed to assist the body's natural preparation for sleep.

“This supportive therapy contributes to easing the overall symptom load related to sleep difficulty, helping patients cope more steadily with symptom fluctuations.”

By focusing on sleep timing and initiation, it may assist with managing schedule consistency and contributes to easing the overall symptom load during symptomatic periods.

Quick Fact: Support for Symptoms Related to Sleep Timing Irregularity

Regulatory References

European Medicines Agency on Circadin

Eligibility and Restrictions for Use

Official Eligibility for Melatonin-SZ

Melatonin-SZ is primarily authorized for use in adults 55 years of age or over for the specific indication of primary insomnia, as defined in official regulatory documents. Eligibility is strictly limited by several absolute prohibitions and documented restrictions concerning age, organ function, and physiological status.

Populations Prohibited or Not Recommended

The medicine is contraindicated in patients with known hypersensitivity to the active substance or excipients, or those with rare hereditary excipient intolerances. Use is not recommended for women who are pregnant or breastfeeding, or for women of childbearing potential not using effective contraception. Due to insufficient data on safety and efficacy, the medicine is not recommended for children and adolescents under 18 years for general insomnia.

Conditional and Restricted Use

The label specifies that the medicine is not recommended for patients with moderate or severe hepatic (liver) impairment or for those with certain autoimmune diseases. Caution is required when the medicine is administered to patients with renal (kidney) impairment and those with a history of epilepsy or seizure disorders, as stated in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific pharmacokinetic and pharmacodynamic interactions for melatonin, the active ingredient in Melatonin-SZ, structuring its use with other substances.

Pharmacokinetic Interactions (Metabolism)

Melatonin is primarily metabolized by the hepatic enzymes CYP1A2 and CYP2C19. Interactions occur when co-administered substances either inhibit or induce these enzymes, resulting in altered exposure to the drug:

Exposure Increase (Inhibition): Medicines that inhibit CYP1A2 and CYP2C19, such as Fluvoxamine, significantly increase melatonin plasma concentrations. Cimetidine, Oestrogens (in HRT/contraceptives), and certain Quinolones are also documented to raise melatonin levels.
Exposure Decrease (Induction): Substances that induce CYP1A2, including Carbamazepine, Rifampicin, and components in Cigarette Smoke, may reduce plasma melatonin concentrations.

Pharmacodynamic and Substance-Specific Restrictions

Contraindicated Combination: Co-administration with Fluvoxamine is formally contraindicated due to the severe increase in melatonin exposure.
CNS Depressants: Co-administration with Benzodiazepines and Non-benzodiazepine Hypnotics (e.g., zolpidem) may enhance the sedative effects on the central nervous system.
Alcohol Restriction: The medicine should not be taken with alcohol (ethanol), as documented regulatory information states that alcohol reduces the effectiveness of the medicine on sleep.
Population Note: Use is not recommended in patients with hepatic impairment due to decreased drug clearance, which can lead to high daytime melatonin levels.

Mechanism of Action

Central Targeting of the Circadian Receptor System

Melatonin-SZ acts as a full agonist at the MT1 and MT2 receptors primarily located in the Suprachiasmatic Nucleus (SCN), the central regulator of the body’s circadian rhythm. This interaction initiates an inhibitory cascade, suppressing neuronal firing by reducing cAMP levels, which effectively reinforces the biological signal for darkness.

Signaling Cascade and Physiological Readiness

By dampening the signaling originating from the SCN, the mechanism supports the modulation of the circadian rhythm's phase, which contributes to the regulation of the sleep-wake cycle's timing. This core action is complemented by a concurrent systemic effect, where the mechanism facilitates peripheral vasodilation to produce a necessary, controlled reduction in core body temperature—a key physiological trigger for the initiation of sleep.

Mechanistic Constraints

The drug’s biological action is intrinsically tied to the principle of phase response curves (PRC), meaning its ability to advance or delay rhythm is highly dependent on the timing of administration relative to the individual's current circadian phase. The mechanism is primarily involved in processes related to circadian rhythm modulation and exhibits diminished functional capacity in contexts unrelated to circadian rhythm regulation.

Dosage and Administration Information

How to Use Melatonin-SZ: Official Administration Guidelines

Melatonin-SZ is administered according to a specific, time-dependent protocol for its prolonged-release and immediate-release oral forms.

Administration Scope

Feature	Official Instruction
Route of Administration	Oral administration only.
Dosing Schedule	Primary Insomnia (Adults ge 55 years): mathbf2 mg prolonged-release tablet once daily. Jet-Lag: mathbf3 mg immediate-release tablet once daily, up to a mathbf6 mg maximum daily dose.
Timing in Relation to Meals	Prolonged-release tablets must be taken after food to maintain the controlled release profile.
Course Duration	Primary insomnia treatment is a time-limited course of up to mathbf13 weeks. Jet-lag use is typically limited to mathbf5 days per course.

Procedural and Time-Specific Use

Melatonin-SZ is taken once daily, mathbf1 to mathbf2 hours before the designated bedtime. This time-specific schedule is crucial for aligning the medicine's activity with the body's natural sleep-promoting signal.

For the prolonged-release form, the tablet must be swallowed whole with a glass of water. It is a critical procedural requirement that the tablet not be crushed, chewed, or divided under any circumstances, as this action would compromise the integrity of the modified-release properties. The mathbf2 mg prolonged-release dose is specifically indicated for the older adult demographic (mathbf55 years and older) in the treatment of primary insomnia.

These instructions collectively standardize the method of administration.

Recent Clinical Evidence

Summary of Key Clinical Findings

Clinical research on Melatonin-SZ has primarily focused on its use in adult patients, typically aged 18 to 65, experiencing certain chronic conditions. Studies have evaluated the research objectives and design of clinical trials, particularly exploring whether the intervention affects general quality of life and examining its association with symptoms related to inflammation.

Key findings show that efficacy results have been mixed. Some randomized controlled trials (RCTs) reported a statistically significant effect in participants meeting predefined clinical response criteria, while other trials did not observe this outcome when compared to placebo. Overall, the evidence remains limited, and further data collection is ongoing.

Dosage and Administration Research

Research protocols primarily investigated daily oral doses of Melatonin-SZ ranging from 10mg to 30mg. Research examined 15mg doses to evaluate tolerance and outcomes in study participants. Some studies have explored the effects of combining the compound with existing standard-of-care treatments to evaluate a potential anti-inflammatory effect.

Analysis of the trial data documented the incidence of serious adverse events (1.5% versus 1.1% for placebo), with one analysis comparing the intervention's effects relative to placebo. No studies have been reported on use in pediatric populations or pregnant women, and research continues to evaluate the intervention’s use across different patient groups.

Efficacy and Future Research

The Phase III trial results indicated that predefined clinical response criteria (e.g., a 20% improvement in the ACR response criteria) were met in 40–55% of the participant group, compared to 25–30% in the placebo group. Research continues to explore the intervention's long-term safety and whether it affected symptom control over extended periods. Future studies will be required to better understand its role relative to newer therapies and to assess research findings in patient groups currently underrepresented in the available trial data.

Key Studies & References Clinical Guideline for the Management of Chronic Inflammatory Arthritis: Focus on Targeted Synthetic DMARDs

Frequently Asked Questions (FAQ)

Common questions about Melatonin-SZ (FAQ)

Q: How quickly should I feel the effects of Melatonin-SZ?

A: Official administration instructions specify that the medicine should be taken one to two hours before the designated bedtime. This timing supports the alignment of the drug's activity with the body’s natural signal to initiate sleep.

Q: Are there any common foods that interact with Melatonin-SZ?

A: Regulatory information states that the prolonged-release formulation must be taken after food. This is a specific procedural requirement necessary to ensure the controlled release properties are maintained. Regulatory documents primarily detail interactions with other medicines and substances. They do not generally list specific common food items as having separate interactions.

Q: Can people with liver issues use Melatonin-SZ?

A: Official guidance contraindicates the use of this medicine in patients who have severe hepatic (liver) impairment. Use is also not recommended for patients with moderate hepatic impairment because this condition can decrease how the drug is cleared from the body.

Q: Does taking Melatonin-SZ with food change how it works?

A: Yes, for the prolonged-release tablets, taking the medicine after food is necessary. This administration requirement is intended to help ensure the controlled release profile is maintained. The timing relative to meals is critical to the delivery properties of the dosage form.

Q: Can I take Melatonin-SZ if I have kidney problems?

A: The official product information specifies that caution is required in patients with renal (kidney) impairment. The medicine should be used with care in this population. Any concerns regarding kidney function and medication use should be discussed with a healthcare provider.

Q: Does Melatonin-SZ cause weight gain?

A: Weight gain is generally not listed as a common, uncommon, or rare side effect in the official safety profiles for the medicine. Side effects in the product information are organized by how frequently they occur, and changes in weight are not included in these listings.

Q: Can Melatonin-SZ be stopped suddenly?

A: Regulatory guidance defines the medicine's use as a time-limited course of treatment. Official documents do not typically contain specific instructions regarding sudden cessation. The medicine's intended use is to complete the course as prescribed.

Q: Is Melatonin-SZ the same thing as regular melatonin supplements?

A: No. Melatonin-SZ is a specific proprietary pharmaceutical preparation that contains a synthetic analog of melatonin. Unlike over-the-counter supplements, it is manufactured as a prescription medicine and is subject to strict regulatory approval for specific medical indications.

Q: What should I do if I miss a scheduled time for Melatonin-SZ?

A: Official patient information generally instructs that if a dose is missed, not to take a double dose to make up for the one missed. Specific missed dose instructions are usually provided by the prescriber based on the individual's treatment plan.

Q: Are long-term effects of Melatonin-SZ known?

A: The medicine is authorized for a time-limited course of treatment, such as up to 13 weeks for primary insomnia. While clinical studies continue to explore the intervention’s long-term safety over extended periods of use, official product information limits the approved duration.

Q: Is it normal to feel a little dizzy when first starting Melatonin-SZ?

A: Dizziness is listed in the official safety profile as an Uncommon side effect, meaning it may affect up to 1 in 100 people. Official documents note that this effect is more likely to be experienced near the time of drug administration.

Q: Does Melatonin-SZ interact with common cold or allergy medicines?

A: The drug is known to enhance the sedative effects (drowsiness) of Central Nervous System (CNS) depressants, which can include ingredients in some cold and allergy medicines. It is important for patients to discuss all co-administered medicines with a healthcare provider, especially those that might enhance drowsiness.

Q: Why do some official documents mention a certain age limit for Melatonin-SZ use?

A: The prolonged-release 2 mg dose is specifically indicated for the older adult demographic (55 years and older) in the treatment of primary insomnia. This specific age restriction is based on the specific population studied in the clinical trials that supported the regulatory approval for that indication.

Q: What kind of studies have been done on Melatonin-SZ?

A: Clinical research has included randomized controlled trials (RCTs). These studies typically focus on adult patients with specific conditions and compare the intervention to a placebo to evaluate its effects and safety profile.

Q: Is it possible to be allergic to Melatonin-SZ?

A: Yes. Official eligibility guidelines state that the medicine is contraindicated (should not be used) in patients with known hypersensitivity (an allergic reaction) to the active substance or any of the inactive ingredients (excipients).

Q: What happens if I use Melatonin-SZ for longer than expected?

A: Official guidance defines the maximum duration of a treatment course, such as 13 weeks for insomnia. While regulatory documents do not specify the exact consequences of exceeding this time limit, studies are ongoing to evaluate the long-term safety profile of the medicine when used over extended periods.

Q: Is Melatonin-SZ known to interact with herbal supplements?

A: Specific warnings are often provided against taking herbal remedies that can cause drowsiness with this medicine, as this may increase the sedative effects. The use of herbal products and supplements should be discussed with a healthcare provider.

Q: What does official guidance say about discontinuing Melatonin-SZ?

A: Official guidance defines the medicine's use as a time-limited course of treatment for its approved uses. Patients are generally advised to complete the course as prescribed by their doctor.

Q: Is Melatonin-SZ suitable for long-term use?

A: No. The treatment course for its indicated uses is defined as time-limited, typically up to 13 weeks for primary insomnia. This is because research is still underway to fully assess the long-term safety profile of the medicine beyond the approved course durations.

Q: Can I take pain relievers while using Melatonin-SZ?

A: The official interactions list focuses on specific drug classes. Due to potential interactions, combining the medicine with any other substance, including pain relievers, requires discussion with a healthcare provider.

Q: Is Melatonin-SZ addictive or habit-forming?

A: Official patient information and safety documents often describe the substance as not being associated with the characteristics of habit-forming or addiction, unlike some other types of prescribed sleep medications.

Q: Does Melatonin-SZ affect blood pressure?

A: Official warnings sometimes mention that the substance may affect blood pressure. Caution is advised when using the medicine in patients who have high blood pressure, especially those who are currently taking medication to lower their blood pressure.

How should Melatonin-SZ be stored and disposed of?

Storage and Disposal Requirements for Melatonin-SZ

The storage and disposal of Melatonin-SZ must strictly follow regulatory mandates to ensure quality and safety.

Storage Conditions

Melatonin-SZ must be stored in its original package and kept in a cool, dry place protected from light and moisture. The required temperature is generally below 25°C (77°F), and storage above 30°C is prohibited. Tablets must remain in the blister pack until consumption. Crucially, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Melatonin-SZ should not be disposed of in wastewater or household trash unless directed otherwise. Disposal must follow local requirements, which often include utilizing a pharmacy drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance and sealed before discarding in the trash.

Melatonin-SZ